Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid

Gastroenterology

Volumn 148, Issue 4, 2015, Pages 751-761.e8

  Hirschfield, Gideon M ^a   Mason, Andrew ^b   Luketic, Velimir ^c,d   Lindor, Keith ^e,f   Gordon, Stuart C ^g   Mayo, Marlyn ^h   Kowdley, Kris V ⁱ   Vincent, Catherine ^j   Bodhenheimer, Henry C ^k,l   Parés, Albert ^m   Trauner, Michael ⁿ   Marschall, Hanns Ulrich ^o   Adorini, Luciano ^p   Sciacca, Cathi ^p   Beecher Jones, Tessa ^p   Castelloe, Erin ^p   Böhm, Olaf ^q   Shapiro, David ^p  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF ALBERTA   (Canada)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^f ARIZONA STATE UNIVERSITY   (United States)

^g HENRY FORD HEALTH SYSTEM   (United States)

^h UNIVERSITY OF TEXAS AT DALLAS   (United States)

ⁱ VIRGINIA MASON MEDICAL CENTER   (United States)

^j CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^k MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^l BETH ISRAEL MEDICAL CENTER   (United States)

^m UNIVERSITY OF BARCELONA   (Spain)

ⁿ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^o UNIVERSITY OF GOTHENBURG   (Sweden)

^p INTERCEPT PHARMACEUTICALS   (United States)

^q FGK Clinical Research   (Germany)

more..

Author keywords

Acids; Bile; Cholestasis; Dose; FXR; Study

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OBETICHOLIC ACID; PLACEBO; TRIACYLGLYCEROL; URSODEOXYCHOLIC ACID; 6-ETHYLCHENODEOXYCHOLIC ACID; CHENODEOXYCHOLIC ACID; CHOLAGOGUE;

ABDOMINAL DISTENSION; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; APPLICATION SITE EXCORIATION; ARTHRALGIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECCHYMOSIS; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HUMAN TISSUE; INSOMNIA; LIMB PAIN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NOSE OBSTRUCTION; OPEN STUDY; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SALIVARY GLAND TUMOR; SIDE EFFECT; SINUSITIS; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; WARTHIN SALIVARY GLAND TUMOR; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; DOSE RESPONSE; LIVER CIRRHOSIS, BILIARY; MIDDLE AGED; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; CHENODEOXYCHOLIC ACID; CHOLAGOGUES AND CHOLERETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; PRURITUS; TREATMENT FAILURE; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 84925362562     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.12.005     Document Type: Article

References (47)

1. G.M. Hirschfield, and M.E. Gershwin The immunobiology and pathophysiology of primary biliary cirrhosis Annu Rev Pathol 8 2013 303 330
2. M.G. Silveira, E.M. Brunt, and J. Heathcote American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis Hepatology 52 2010 349 359
3. C. Corpechot, F. Carrat, and A. Bahr The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis Gastroenterology 128 2005 297 303
4. J. Lee, A. Belanger, and J.T. Doucette Transplantation trends in primary biliary cirrhosis Clin Gastroenterol Hepatol 5 2007 1313 1315
5. P.J. Trivedi, W.J. Lammers, and H.R. van Buuren Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study Gut 2015 Jan 7 Epub ahead of print.
6. R.E. Poupon, K.D. Lindor, and K. Cauch-Dudek Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis Gastroenterology 113 1997 884 890
7. J. Shi, C. Wu, and Y. Lin Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials Am J Gastroenterol 101 2006 1529 1538
8. C. Corpechot, L. Abenavoli, and N. Rabahi Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis Hepatology 48 2008 871 877
9. C. Corpechot, O. Chazouilleres, and R. Poupon Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome J Hepatol 55 2011 1361 1367
10. E.M. Kuiper, B.E. Hansen, and R.A. de Vries Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid Gastroenterology 136 2009 1281 1287
11. M. Carbone, G.F. Mells, and G. Pells Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid Gastroenterology 144 2013 560 569
12. R.E. Poupon, B. Balkau, and E. Eschwege A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group N Engl J Med 324 1991 1548 1554
13. E.J. Heathcote, K. Cauch-Dudek, and V. Walker The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis Hepatology 19 1994 1149 1156
14. R.E. Poupon, R. Poupon, and B. Balkau Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group N Engl J Med 330 1994 1342 1347
15. K.D. Lindor, T.M. Therneau, and R.A. Jorgensen Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis Gastroenterology 110 1996 1515 1518
16. K.D. Lindor, R.A. Jorgensen, and T.M. Therneau Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis Mayo Clin Proc 72 1997 1137 1140
17. C. Degott, E.S. Zafrani, and P. Callard Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression Hepatology 29 1999 1007 1012
18. P. Angulo, E.R. Dickson, and T.M. Therneau Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial J Hepatol 30 1999 830 835
19. A. Pares, L. Caballeria, and J. Rodes Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid Gastroenterology 130 2006 715 720
20. S. Mudaliar, R.R. Henry, and A.J. Sanyal Efficacy and safety of the farnesoid x receptor agonist obeticholic Acid in patients with type 2 diabetes and nonalcoholic fatty liver disease Gastroenterology 145 2013 574 582
21. R. Pellicciari, S. Fiorucci, and E. Camaioni 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity J Med Chem 45 2002 3569 3572
22. X.X. Wang, T. Jiang, and Y. Shen Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model Diabetes 59 2010 2916 2927
23. Y.T. Li, K.E. Swales, and G.J. Thomas Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration Arterioscler Thromb Vasc Biol 27 2007 2606 2611
24. K.D. Lindor, M.E. Gershwin, and R. Poupon Primary biliary cirrhosis Hepatology 50 2009 291 308
25. T. Kumagi, M. Guindi, and S.E. Fischer Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis Am J Gastroenterol 105 2010 2186 2194
26. C. Meaney, T. Kumagi, and N. Al-Harthy Developing end points for clinical trials in PBC: alkaline phosphatase as a predictor of outcome Hepathology Suppl S363 2011 Abstract 1296
27. N. Momah, M.G. Silveira, and R. Jorgensen Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis Liver Int 32 2012 790 795
28. D. Tagliacozzi, A.F. Mozzi, and B. Casetta Quantitative analysis of bile acids in human plasma by liquid chromatography-electrospray tandem mass spectrometry: a simple and rapid one-step method Clin Chem Lab Med 41 2003 1633 1641
29. C. Gälman, I. Arvidsson, and B. Angelin Monitoring hepatic cholesterol 7alpha-hydroxylase activity by assay of the stable bile acid intermediate 7alpha-hydroxy-4-cholesten-3-one in peripheral blood J Lipid Res 44 2003 859 866
30. Y. Hochberg A sharper Bonferroni procedure for multiple tests of significance Biometrika 75 1988 800 802
31. P. Lefebvre, B. Cariou, and F. Lien Role of bile acids and bile acid receptors in metabolic regulation Physiol Rev 89 2009 147 191
32. M. Makishima, A.Y. Okamoto, and J.J. Repa Identification of a nuclear receptor for bile acids Science 284 1999 1362 1365
33. R. Poupon Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action Clin Res Hepatol Gastroenterol 36 Suppl 1 2012 S3 S12
34. S. Hohenester, L.M. Wenniger, and C.C. Paulusma A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes Hepatology 55 2012 173 183
35. U. Beuers, G.A. Kullak-Ublick, and T. Pusl Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators? Clin Rev Allergy Immunol 36 2009 52 61
36. K.L.V.A. Kowdley, D.E. Jones, and R.W. Chapman The first new monotherapy therapeutic PBC study in a decade? An international study evaluating the farnesoid X receptor agonists obeticholic acid in PBC Hepatology 54 2011 416A 417A
37. W.J. Lammers, H.R. van Buuren, and G.M. Hirschfield Levels of alkaline phosphatase and bilirubin are surrogate endpoints of outcomes of patients with primary biliary cirrhosis - an international follow-up study Gastroenterology 147 2014 1338 1349.e5
38. J.M. Shapiro, H. Smith, and F. Schaffner Serum bilirubin: a prognostic factor in primary biliary cirrhosis Gut 20 1979 137 140
39. A.E. Kremer, R. van Dijk, and P. Leckie Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions Hepatology 56 2012 1391 1400
40. F. Alemi, E. Kwon, and D.P. Poole The TGR5 receptor mediates bile acid-induced itch and analgesia J Clin Invest 123 2013 1513 1530
41. P.A. Dawson, and S.J. Karpen Bile acids reach out to the spinal cord: new insights to the pathogenesis of itch and analgesia in cholestatic liver disease Hepatology 59 2014 1638 1641
42. G. Rizzo, D. Passeri, and F. De Franco Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist Mol Pharmacol 78 2010 617 630
43. A. Sorokin, J.L. Brown, and P.D. Thompson Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review Atherosclerosis 194 2007 293 299
44. C.J. Sinal, M. Tohkin, and M. Miyata Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis Cell 102 2000 731 744
45. A. Rigotti, B.L. Trigatti, and M. Penman A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism Proc Natl Acad Sci U S A 94 1997 12610 12615
46. E. Hambruch, S. Miyazaki-Anzai, and U. Hahn Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice J Pharmacol Exp Ther 343 2012 556 567
47. A. Mencarelli, B. Renga, and E. Distrutti Antiatherosclerotic effect of farnesoid X receptor Am J Physiol Heart Circ Physiol 296 2009 H272 H281